| The prevalence of significant fibrosis in chronic hepatitis B patients with ALT <80 IU/L |
|
Woo Jin Lee, Seung Ha Park, Dong Joon Kim, Sung Hoa Lee, Chan Woo Lee, Kyu Tae Park, Jae Youn Cheong, Sung Won Cho, Seong Gyu Hwang, Youn Jae Lee, Mong Cho, Jin Mo Yang, Young Bae Kim |
|
|
| ALT<80 IU/L인 만성 B형 간염 환자의 중등도 이상 간섬유화 유병률 |
|
이우진, 박승하, 김동준, 이성화, 이찬우, 박규태, 정재연, 조성원, 황성규, 이연재, 조 몽, 양진모, 김영배 |
|
|
|
|
|
|
| Abstract |
|
Background/Aims: The aims of this study were to investigate the prevalence of significant fibrosis in patients with chronic hepatitis B (CHB) virus infections and alanine aminotransferase (ALT) <80 IU/L, and to develop a noninvasive predictive model for significant fibrosis.
Methods: The 136 patients with CHB who underwent liver biopsy were recruited from six tertiary hospitals. The diagnostic value of predictors was judged using multivariate logistic modeling and the area under the receiver operating characteristic (AUROC)
curve.
Results: Significant fibrosis was diagnosed in 97 patients (71.3%, 95% CI, 63.7~78.9%). In the training set (n = 85), the most important clinical data for predicting significant fibrosis were age and aspartate aminotransferase (AST). The AUROC of this model was 0.86 (95% CI, 0.78~0.94). The validation set (n=51), obtained from another institute, yielded similar results [AUROC: 0.90
(95% CI, 0.78~0.99)].
Conclusions: A high prevalence of significant fibrosis in CHB patients with ALT <80 IU/L was observed. A simple model that
includes age and AST provides an easily applicable tool for physicians to guide the decision-making process regarding the need to perform a liver biopsy in individual patients. However, additional studies are needed to explore the model’s performance in larger, independent patient populations. (Korean J Med 78:68-74, 2010) |
| Key Words:
Hepatitis B, chronic; Fibrosis; Prediction; Model |
|
PDF Links
Full text via DOI
Download Citation
